Chandler Park, MD

Articles by Chandler Park, MD

High-Risk BCG-Naive NMIBC: Where Treatment Falls Short Today

ByNeal D. Shore, MD, FACS,Chandler Park, MD

August 18th 2026

Neal D. Shore, MD, FACS, and Chandler Park, MD, share how the POTOMAC data, and a newly FDA-approved combination, are opening up shared decision-making with patients.

Latest Updated Articles

Chandler Park, MD

Articles by Chandler Park, MD

High-Risk BCG-Naive NMIBC: Where Treatment Falls Short Today

Latest Updated Articles

Trending on Urology Times

FDA receives NDA submission for UGN-103 in recurrent LG-IR-NMIBC

Active surveillance use for low-risk prostate cancer reaches 93% in VA System

HoLEP learning curve and strategies for successful adoption, with Daniel S. Kellner, MD

Focal therapy for prostate cancer frequently used outside guideline-supported groups

Radium-223 fails to improve skeletal event-free survival in metastatic RCC